Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$0.04
$0.04
$0.04
$2.46
N/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.13
-1.4%
$2.21
$1.62
$14.67
$5.05M0.98955,109 shs76,623 shs
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
$2.95
+3.9%
$4.01
$2.11
$168.00
$4.53M-0.08140,227 shs373,814 shs
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
$0.00
+114.3%
$0.00
$0.00
$0.00
$1.42M0.14491,208 shs12,000 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00%0.00%0.00%0.00%0.00%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-1.39%-1.39%0.00%+21.02%-69.66%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
+3.87%+5.73%+23.75%-68.07%-96.64%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00%+36.36%+114.29%-21.05%+50.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.4631 of 5 stars
0.04.00.00.01.00.00.6
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.9378 of 5 stars
0.05.00.00.00.80.01.3
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00
N/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.00
N/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$9.14M0.32N/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.21M0.97N/AN/A$2.59 per share0.82
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/A$27.05 per shareN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARAVIVE, INC stock logo
ARAV
ARAVIVE
-$76.32MN/A0.00N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$15.04M-$307.86N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
-$2.10MN/A0.00N/AN/AN/AN/AN/A

Latest RSPI, ARAV, REVB, and ENSC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$1.02N/AN/AN/A$0.67 millionN/A
8/8/2025N/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$4.46N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
5/8/2025Q1 2025
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$20.64-$6.33+$14.31-$2.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
2.50
2.50
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/A
3.60
3.60
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ARAVIVE, INC stock logo
ARAV
ARAVIVE
35.80%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
12.80%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
ARAVIVE, INC stock logo
ARAV
ARAVIVE
60.40%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
2.30%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
50.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
ARAVIVE, INC stock logo
ARAV
ARAVIVE
2073.56 million29.13 millionNo Data
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million2.18 millionNot Optionable
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
101.53 million1.50 millionNot Optionable
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
2949.46 million474.45 millionNot Optionable

Recent News About These Companies

RespireRx Pharmaceuticals Inc (RSPI)
RespireRx Pharmaceuticals Inc RSPI
RCKT Rocket Pharmaceuticals, Inc.
Other OTC Pharmaceuticals - Haiti
Other OTC Pharmaceuticals - Vietnam
Other OTC Pharmaceuticals - Finland
Alnylam Pharmaceuticals (NASDAQ: ALNY)

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAVIVE stock logo

ARAVIVE NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/18/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.13 -0.03 (-1.39%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.12 -0.01 (-0.47%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Revelation Biosciences stock logo

Revelation Biosciences NASDAQ:REVB

$2.95 +0.11 (+3.87%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.95 0.00 (0.00%)
As of 07/18/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Cortex Pharmaceuticals stock logo

Cortex Pharmaceuticals OTCMKTS:RSPI

$0.0015 +0.00 (+114.29%)
As of 07/18/2025 03:34 PM Eastern

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.